Condition

HER-2 Positive Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 28 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials28
Recruiting1
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

28 shown
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast CancerNCT07506876 · 2026-04-27
RECRUITING
Gut Microbiome Changes During Abemaciclib Therapy in Breast CancerNCT07406594 · 2027-10-01
NOT_YET_RECRUITING
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)NCT07565324 · 2026-04-30
NOT_YET_RECRUITING
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast CancerNCT05871918 · 2022-10-08
UNKNOWN
PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter StudyNCT04644406 · 2020-12-01
UNKNOWN
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · 2017-06-21
ACTIVE_NOT_RECRUITING
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerNCT02675231 · 2016-05-23
COMPLETED
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerNCT02598310 · 2015-11-01
TERMINATED
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 · 2015-08-24
COMPLETED
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCANCT02326974 · 2015-01-01
ACTIVE_NOT_RECRUITING
A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerNCT02488564 · 2014-12-17
COMPLETED
Neoadjuvant Response-guided Treatment of HER2 Positive Breast CancerNCT02568839 · 2014-11-01
ACTIVE_NOT_RECRUITING
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerNCT02066532 · 2014-06-01
COMPLETED
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT02154529 · 2014-05-01
TERMINATED
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast CancerNCT02102438 · 2014-04-01
WITHDRAWN
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)NCT01583426 · 2012-07-01
COMPLETED
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast CancerNCT01677455 · 2012-07-01
COMPLETED
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1NCT01565200 · 2012-05-01
COMPLETED
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain MetastasesNCT01305941 · 2011-09-01
COMPLETED
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and TrastuzumabNCT01432223 · 2011-09-01
COMPLETED
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast CancerNCT01426880 · 2011-08-01
COMPLETED
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast CancerNCT01388647 · 2011-08-01
TERMINATED
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast CancerNCT01428414 · 2011-08-01
UNKNOWN
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast CancerNCT01361945 · 2011-07-01
WITHDRAWN
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast CancerNCT01340430 · 2011-03-01
COMPLETED
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerNCT02131506 · 2009-12-01
TERMINATED
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 YearsNCT01433926 · 2009-09-01
COMPLETED
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast CancerNCT00788931 · 2008-12-01
COMPLETED

Common interventions

TrastuzumabDRUG12CarboplatinDRUG4Nab-paclitaxelDRUG3PaclitaxelDRUG3PertuzumabDRUG3FulvestrantDRUG2T-DM1DRUG289Zr-trastuzumabPROCEDURE1AbemaciclibDRUG1AnastrozoleDRUG1AUY922DRUG1background treatmentDRUG1Concurrent endocrine therapy with the chemotherapy and HER2 directed therapyDRUG1CyclophosphamideDRUG1DocetaxelDRUG1docetaxel + trastuzumab sc + pertuzumabDRUG1Efficacy of the Pertuzumab-Trastuzumab combinationOTHER1EpirubicinDRUG1eribulinDRUG1EverolimusDRUG1Excision of tumor/mastectomyPROCEDURE1ExemestaneDRUG1ganetespibDRUG1IV LBH589DRUG1Lapatinib, CaelyxDRUG1

Trial status mix

COMPLETED13
TERMINATED4
ACTIVE_NOT_RECRUITING3
UNKNOWN3
NOT_YET_RECRUITING2
WITHDRAWN2
RECRUITING1

Phase mix

PHASE218
PHASE16
PHASE36
NA2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.